What is the definition of bone marrow transplant survival rate?
Blood and marrow transplantation (BMT) is a procedure used to treat cancers that do not respond to traditional chemotherapy and to correct inherited disorders of the bone marrow.
The BMT survival rate measures the percentage of patients who receive this treatment and survive for a specific period of time. The data is further broken down by the stem cell source, which also relates to the risk of the treatment:
- Autologous: stem cells from the patient
- Allogenic: stem cells from another donor, such as a sibling, parent or an unrelated donor
Why do we measure bone marrow transplant survival rates?
At the Pediatric Blood and Marrow Transplant and Cellular Therapeutics Program at Children's Hospital Colorado, we measure BMT success rates to better understand the effectiveness of treatments and to improve patient outcomes.
These evaluations let us know where to put our efforts in improving transplant outcomes. This is all part of the work we do to provide the best care for babies, kids, adolescents and young adults undergoing BMT for cancer or noncancerous blood diseases.
Our blood and marrow transplant survival rates
100-day survival rate for autologous bone marrow transplants
100-day survival rate for allogeneic bone marrow transplants
Years of our program meeting or exceeding international standards
Below is a graph of the 100-day and one-year survival rates of 437 patients. These patients all received bone marrow transplants at Children’s Colorado between 2010 and 2019.
Children's Colorado blood and marrow transplant survival rates from 2010 to 2019
How do Children's Colorado’s success rates compare to other BMT centers?
To understand how our program's performance compares with other hospitals, we participate in the Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of survival rates. CIBMTR matches our Children’s Colorado transplant patients to similar patients who have had transplants elsewhere around the United States considering key patient variables such as age, disease and donor type.
The most recent CIBMTR analysis was performed on transplants performed at Children’s Colorado from Jan. 1, 2015 through Dec. 31, 2017 using related and unrelated donors. It only included patients who had at least 100 days of post-transplant follow-up. While CIBMTR compares our performance to international standards on a continual basis, this specific analysis was done only with centers in the United States.
How does Children’s Colorado’s data compare?
For the Jan. 1, 2015 through Dec. 31, 2017 analysis, Children's Colorado reported survival status data for 96 patients.
- The actual one-year survival rate of these patients was 90.6%.
- The predicted one-year survival range was from 74.1% to 89.0%.
This means that the survival outcomes of the Blood and Marrow Transplant and Cellular Therapy Program at Children's Colorado exceeded the expected one-year survival, when compared to a similar group of patients transplanted at other pediatric centers in the United States.
Every year since 2010, CIBMTR has conducted an analysis of each participating center’s allogeneic transplant survival rate compared to international standards. Over the nine years of these analyses, our program has always met or exceeded international standards.
How are we able to improve survival rates and other transplant outcomes?
We have improved BMT patient survival rates and other outcomes through our clinical approach, research studies and commitment to quality measures.
We believe provider expertise and continuity of care is critically important for patient outcomes. Our providers have specific training in BMT and cellular therapy. We also provide a variety of services to aid in the recovery after transplantation including physical therapy, child life and medical care from nurses and doctors from many different subspecialties.
To provide the best care and to make this experience more personalized, we have implemented a “door to door” model. Through this model, we assign a nurse who has expertise in the child’s condition to each patient and family. This nurse is the patient and family’s main point of contact during the entire transplant process and partners with your doctor to provide the very best care throughout your transplant procedure.
Our physicians are leaders in the Children’s Oncology Group (COG) and the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). Our pediatric experts help design and participate in national and international clinical trials. These studies test new approaches to pediatric BMT and advanced cellular therapeutics, with the goal of improving outcomes.
Since 2018, our program has offered advanced cellular therapies including cells to treat infections that occur during transplantation. We also offer chimeric antigen receptor T cell (CAR) therapy, which has greatly improved outcomes for patients with leukemia that is resistant to all other therapies. Our program offers both commercial forms of CAR T cell therapy. We are also now starting to use this approach in patients with other types of cancers.
In addition to the above clinical trials, many of our team members also perform basic laboratory research to devise new transplant approaches, methods to treat complications and prevent relapse. Our investigators hold grants from the National Institute of Health (NIH), Department of Defense (DOD), Leukemia and Lymphoma Society, Hyundai Hope on Wheels, St. Baldrick’s Foundation, Alex’s Lemonade Stand Foundation and many other organizations.
Since 2000, our program has had a comprehensive quality assurance (QA) program that looks at performance on an ongoing basis. The BMT Quality Assurance Program at Children’s Colorado operates in accordance with national guidelines established by the Foundation for Accreditation of Cellular Therapy (FACT). The BMT Program at Children’s Colorado has been FACT-accredited for transplant continuously since 2001, and in 2020, was also granted Immune Effector Cell accreditation.
We have always made patient safety at Children’s Colorado the highest priority by including all providers and caregivers, including patients and families in the BMT process. Our teams are committed to following the best care protocols available while working to advance treatments for the future.
Learn more about our Blood and Marrow Transplant and Cellular Therapy Program.